14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DNLI vs BHVN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over Denali Therapeutics Inc. (DNLI) on higher Unified Composite conviction (42.1/100 HOLD vs. 55.5/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while DNLI wins 3–2 across the 6-pillar growth and valuation breakdown. DNLI trades at $18.32 (N/M Forward P/E, -2481.1% operating margin) versus BHVN at $13.95 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While DNLI currently prints a higher short-term Unified Composite Score (55.5/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -2481.1% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).
Technical & Structure Timing Caution: DNLI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DNLI vs BHVN. Trailing 12-month operating profitability (DNLI -2481.1% vs BHVN 0.0%) and valuation multiples (DNLI N/M vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ DNLI vs BHVN Key Questions & Quantitative Answers
As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over Denali Therapeutics Inc. (DNLI) on higher Unified Composite conviction (42.1/100 HOLD vs. 55.5/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while DNLI wins 3–2 across the 6-pillar growth and valuation breakdown. DNLI trades at $18.32 (N/M Forward P/E, -2481.1% operating margin) versus BHVN at $13.95 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DNLI currently prints a higher short-term Unified Composite Score (55.5/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -2481.1% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY). Technical & Structure Timing Caution: DNLI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DNLI leads the Growth & Scale pillar: DNLI posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (N/A gross margin, -2481.1% operating margin), compared with BHVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DNLI generates $21M in USD-normalized revenue versus N/A for BHVN. In operating R&D and SG&A reinvestment, DNLI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BHVN.
DNLI screens cheaper on headline valuation multiples. DNLI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 138.2x EV/Revenue (unreported FCF margin), whereas BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DNLI (-33.9% ROE) versus BHVN (-799.5% ROE) capital efficiency.
In options market volatility and institutional positioning, DNLI carries 78.2% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 6.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.37β · 48% Vol realized risk). By comparison, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.40β · 111% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.